Morphic to Participate in Jefferies Global Healthcare Conference
Morphic Therapeutic (Nasdaq: MORF) announced its participation in the 2024 Jefferies Global Healthcare Conference. The event will feature a fireside chat with members of the company's management team. The session is scheduled for June 5th at 10:30 AM ET and will be webcast live on Morphic's website, with an archived replay available afterward. Morphic is a biotechnology firm focused on developing oral integrin therapies for chronic diseases.
- Participation in a prominent healthcare conference can increase visibility and investor interest.
- Webcasting the event live and providing an archived replay ensures broad accessibility.
- Focus on developing innovative oral integrin therapies reflects strong R&D efforts in chronic disease treatment.
- No specific details on financial performance or clinical trial progress were provided, limiting actionable insights for investors.
- The announcement lacks information on new partnerships or business developments, which may disappoint some stakeholders.
WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will take part in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5th, at 10:30 AM ET.
A live webcast of the panel discussion and fireside chat at the Jefferies Global Healthcare Conference will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.
About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.
Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718
FAQ
When will Morphic Therapeutic participate in the Jefferies Global Healthcare Conference?
What is Morphic Therapeutic's stock symbol?
Where can I watch the live webcast of Morphic's fireside chat at the Jefferies Global Healthcare Conference?
Will there be a replay available for Morphic's presentation at the Jefferies Global Healthcare Conference?
What type of therapies is Morphic Therapeutic developing?
